To the Company's knowledge, no proceedings have been initiated against the Company at this time, although the Company cannot predict whether or when proceedings might be initiated. The Company intends to cooperate with the government's investigation.
"DaVita has been involved in several investigations over the last 9 years, including some covering issues that are repeated in this subpoena. We respect the government's need to ensure the appropriateness of healthcare provider practices, especially during times when pharmaceutical issues involve significant expense for Medicare. We look forward to meeting with government representatives on this new investigation and once again demonstrating the strength of our clinical outcomes and the integrity and comprehensiveness of DaVita's Compliance programs," said LeAnne Zumwalt, spokesperson for DaVita.
DaVita is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,400 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 110,000 patients.
First Call Analyst:
FCMN Contact: LeAnne.Zumwalt@davita.com
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk,
SOURCE: DaVita Inc.
CONTACT: LeAnne Zumwalt of DaVita Inc., +1-650-696-8910
Web site: http://www.davita.com/